Welcome to our dedicated page for Icon Plc news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.
ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.
Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.
ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.
This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.
Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.
ICON plc (NASDAQ: ICLR) announced that all resolutions during its Annual General Meeting on July 26, 2022, were approved by shareholders. Key resolutions included the re-election of directors and the authorization to allot shares. Major retirements from the Board were noted, including Professor William Hall and Ms. Mary Pendergast, who have served since 2013 and 2014, respectively. The meeting reflects ICON's commitment to governance and shareholder engagement, with approximately 68.8 million votes cast on various resolutions, affirming shareholder confidence.
ICON plc (NASDAQ: ICLR) reported strong Q2 2022 results with net business wins of $2,323 million and a book-to-bill ratio of 1.20. Revenue reached $1,935.2 million, up 122.1% year-over-year. Adjusted EBITDA stood at $354.3 million, 18.3% of revenue, reflecting a yearly increase of 120.2%. Adjusted net income was $235.8 million, with earnings per share of $2.86. The company revised its full year 2022 revenue guidance to $7,690 - $7,810 million, anticipating a 40.3% to 42.5% increase year-over-year.
ICON, a leading healthcare intelligence and clinical research organization (NASDAQ: ICLR), will release its financial results for Q2 2022 on July 27, 2022, after market close. A conference call to discuss these results is scheduled for July 28, 2022, at 8:00am ET. This announcement underscores ICON's dedication to transparency and investor communication. As of March 31, 2022, ICON employed approximately 39,300 individuals across 138 locations globally, emphasizing its expansive operational capacity.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 AM ET. Additionally, CEO Steve Cutler is set to present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM ET, with live webcasts available. As of March 31, 2022, ICON employed approximately 39,300 employees across 138 locations in 53 countries, providing outsourced services in clinical research to various sectors. For updates, visit the Investor section on ICON's website.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, announced that CFO Brendan Brennan will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:20 PM PT. The presentation details will be available on their Investor Relations website, under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 39,300 staff across 138 locations in 53 countries, providing services to various health organizations.
ICON plc (NASDAQ: ICLR) reported a robust first quarter for 2022, achieving record net business wins of $2,426 million and a book to bill ratio of 1.28. Revenue increased by 121.6% year on year to $1,902 million, with adjusted EBITDA growing 124.5% to $340.6 million. The company maintained a closing backlog of $19.6 billion and reaffirmed full-year revenue guidance of $7,770 - $8,050 million. Notably, a $300 million early repayment was made on Term Loan B, reducing net debt to $4.58 billion.
ICON plc (NASDAQ:ICLR), a leader in healthcare intelligence and clinical research, will host a live webcast of its Analyst Day on March 17, 2022, at 12:30 PM ET in Blue Bell, Philadelphia. The event will feature presentations from ICON's executive team and will conclude around 3:30 PM ET, followed by a Q&A session. Updates and links to the webcast will be available in the Investor section of ICON's website.
ICON, headquartered in Dublin, employs approximately 38,330 people across 142 locations globally, offering outsourced services to various organizations.
ICON plc (NASDAQ:ICLR) reported remarkable financial results for Q4 and the full year 2021. The company achieved record net business wins of $2,378 million in Q4, elevating the full-year total to $6,958 million, with a book to bill ratio of 1.27. Q4 adjusted revenue surged 147.4% year-over-year to $1,881.1 million, and the full-year revenue rose by 95.9% to $5,480.8 million. Adjusted EBITDA reached $332.5 million for Q4 and $970.0 million for the full year. The company reaffirmed its revenue guidance for 2022, projecting growth between 41.8% and 46.9%.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that CFO Brendan Brennan will present at the Citi Healthcare Conference on February 24, 2022, at 11:45 AM ET. This event will provide valuable insights into ICON's operations and contributions to healthcare research. For updates, including live webcast links, visit the Investor section of ICON's website under 'Events.' Headquartered in Dublin, Ireland, ICON employs approximately 37,960 staff across 159 locations in 53 countries, focusing on advancing clinical research from molecule to medicine.
ICON plc (NASDAQ: ICLR) forecasts full-year 2022 revenue between
FAQ
What is the current stock price of Icon Plc (ICLR)?
What is the market cap of Icon Plc (ICLR)?
What services does ICON plc provide?
Where is ICON plc headquartered?
What is ICON's role in pharmaceutical development?
Does ICON offer standalone and integrated services?
What is pharmacovigilance, and does ICON provide it?
What industries does ICON serve?
What makes ICON a leader in its industry?
How can I stay updated on ICON's latest news and developments?
What are some of ICON's ancillary services?